• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 257

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

From Huxley to Heffter: Mark Geyer Reflects on a Life in Psychedelic Research

Advanced Shadow Work and Psychedelic Integration: A Jungian Path to Wholeness

Essentials of Psychedelic Therapy & Integration

Pα+ Psychedelic Bulletin #206: Q2’25 Psychedelic Lobbying; Tabernanthalog’s Neuroplasticity Pathway; UK Moves to Ease Schedule I Research Restrictions

GLP-1 Drugs, Psilocybin Mushrooms, and the Case for Sublingual Psilocin

PTSF55 – Creativity, Group Ceremony, and Astral Projection

PharmaTher Provides Update on Psychedelic Product Programs

Silo Wellness Announces Intellectual Property Licensing Agreement of Psilocybin Nasal Spray...

Albert Labs Appoints Mackie Research As Lead Agent For Private Placement...

New England Journal of Medicine publishes exploratory study showing signals of...

4 Ways to Help Destigmatize Psychedelic Therapy in the Black Community

Study Suggests Beneficial Effects of Psilocybin Are Independent of 5-HT2A

Psyched Wellness Receives DTC Eligibility

GH Research Announces Closing of $125 Million Oversubscribed Series B Financing

Red Light Holland Enters into Letter of Intent to Acquire Controlling...

1...256257258...294Page 257 of 294

EDITOR PICKS

From Huxley to Heffter: Mark Geyer Reflects on a Life in...

Advanced Shadow Work and Psychedelic Integration: A Jungian Path to Wholeness

Essentials of Psychedelic Therapy & Integration

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©